GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs

GSK and Eli Lilly have announced plans to expand their manufacturing operations in the U.S., a move that not only boosts local job creation but also helps mitigate the impact of potential tariffs. This is significant as it reflects a growing trend among multinational drugmakers to invest in American production, ensuring a more resilient supply chain and supporting the economy.